Naltrexone and Buprenorphine

Overview

Two Medications, One Receptor System

Naltrexone and buprenorphine both act at the mu-opioid receptor, but their pharmacological profiles produce very different clinical effects. Naltrexone blocks the receptor entirely, so any opioid administered while a person is on naltrexone has greatly reduced effect. Buprenorphine partially activates the receptor while also binding so tightly that it displaces other opioids — producing partial relief from withdrawal and craving while limiting the euphoric and respiratory depressant effects of subsequent opioid use.

This pharmacological logic is the foundation of medication for opioid use disorder (MOUD, sometimes still called MAT — medication-assisted treatment). Methadone, a full opioid agonist, is the third major MOUD medication and is dispensed in regulated opioid treatment programs. Naltrexone and buprenorphine are the office-based, outpatient mainstays for most patients.

The Mortality Question

Opioid use disorder carries a mortality rate dominated by overdose. Untreated, the annual mortality rate is striking. Treatment with buprenorphine or methadone reduces this mortality by approximately half, and in some analyses considerably more. Naltrexone (particularly the extended-release injection, Vivitrol) also reduces mortality, though the evidence base is somewhat smaller and induction is more challenging. The mortality benefit from MOUD is one of the strongest in all of medicine — comparable to or exceeding interventions for cardiovascular disease.

Why They Are Underused

Despite this evidence, only a fraction of people who could benefit from MOUD receive it. Reasons include stigma against medication treatment for addiction, the historic regulatory framework that required a special "X-waiver" to prescribe buprenorphine (eliminated in the US in 2023), shortages of trained prescribers, lack of insurance coverage in some settings, and persistent misconceptions equating maintenance medication with continued addiction. Advocacy and policy work continue to address these barriers.

How They Work

Naltrexone: Opioid Antagonist

Naltrexone is a competitive antagonist at mu-opioid receptors with smaller activity at kappa- and delta-receptors. By occupying the receptor without activating it, naltrexone blocks the effects of opioids — euphoria, analgesia, respiratory depression, and sedation are all attenuated or eliminated at therapeutic naltrexone doses.

For alcohol use disorder, naltrexone reduces the rewarding effects of drinking. Alcohol triggers endogenous opioid release that contributes to its pleasurable effects; blocking this opioid signaling reduces craving and the reinforcing effect of drinking. This is the pharmacological basis for the Sinclair Method, in which naltrexone is taken before drinking events to extinguish the conditioned reinforcement of alcohol over time.

Buprenorphine: Partial Agonist

Buprenorphine is a partial agonist at the mu-opioid receptor and has a very high binding affinity. This combination produces several clinically important features:

• Ceiling effect: Above moderate doses, additional buprenorphine produces little additional opioid effect, including respiratory depression. This is one reason buprenorphine has a wider safety margin than full agonists.
• Receptor blockade: Because buprenorphine binds tightly, it displaces and blocks other opioids. A person stable on buprenorphine derives little additional effect from heroin, fentanyl, or oxycodone.
• Long duration: Buprenorphine's half-life is long, allowing once-daily or even less frequent dosing.
• Withdrawal management: Partial agonism is sufficient to relieve opioid withdrawal symptoms in most patients without producing significant euphoria.

Precipitated Withdrawal

Because buprenorphine binds tightly and only partially activates the receptor, giving it to a person who currently has full agonist opioids active in their system can displace those agonists and substitute much weaker activation — abruptly precipitating withdrawal symptoms. This is why buprenorphine induction is timed to begin only after the patient is already in mild-to-moderate spontaneous withdrawal. In the era of fentanyl, induction has become more complex, because fentanyl accumulates in adipose tissue and can produce delayed-onset precipitated withdrawal.

Naloxone in Combination Products

Most buprenorphine products for office-based treatment combine buprenorphine with naloxone (e.g., Suboxone). When taken sublingually as directed, the naloxone has minimal effect because of poor sublingual absorption. If the product is injected, however, naloxone becomes bioavailable and antagonizes opioid effects — discouraging misuse by injection. Subutex (buprenorphine alone) is used in select populations, particularly during pregnancy.

Major Medications in This Class

Naltrexone — Oral Forms

Oral naltrexone (ReVia, Depade, and generics) is typically dosed at 50 mg once daily for both AUD and OUD. Adherence is the primary challenge — patients can simply stop taking the pill to use opioids or alcohol again.

Naltrexone — Extended-Release Injection (Vivitrol)

Vivitrol is a monthly intramuscular injection of 380 mg of extended-release naltrexone. It provides continuous opioid blockade for approximately 4 weeks. Vivitrol addresses the adherence problem of oral naltrexone and is the more commonly used formulation in modern OUD treatment when naltrexone is chosen. Initiation requires 7–14 days of complete opioid abstinence to avoid precipitated withdrawal.

Buprenorphine — Sublingual Combinations

Suboxone (buprenorphine/naloxone) and Zubsolv are the most common sublingual products. Doses are typically 8–16 mg per day after induction, with some patients on higher doses. Films and tablets dissolve under the tongue or in the cheek and are absorbed through the oral mucosa — swallowing reduces bioavailability.

Buprenorphine — Monoproduct (Subutex)

Subutex (buprenorphine alone, without naloxone) is used selectively, including during pregnancy, where it is sometimes preferred to avoid theoretical risks of naloxone exposure.

Buprenorphine — Extended-Release Injection (Sublocade)

Sublocade is a once-monthly subcutaneous injection of buprenorphine, typically used after stabilization on sublingual buprenorphine. It provides continuous therapeutic levels for a month, eliminating daily dosing and reducing the burden of adherence and potential diversion.

Buprenorphine Implant (Probuphine)

Probuphine is a subdermal implant that delivers buprenorphine over six months. It is used in selected stable patients on low-dose maintenance. It is less widely used than other formulations.

Buprenorphine for Pain (Belbuca, Butrans)

Belbuca (buccal film) and Butrans (transdermal patch) are formulations of buprenorphine marketed for chronic pain. They use lower doses than those typical for OUD and have a separate FDA-approved indication for moderate to severe pain.

FDA-Approved and Off-Label Uses

Naltrexone for Alcohol Use Disorder

Both oral naltrexone and Vivitrol are FDA-approved for alcohol use disorder. They reduce heavy drinking days, craving, and the rewarding effect of alcohol. Unlike older paradigms, naltrexone does not require complete abstinence — patients can drink while taking it, and the medication is intended to reduce the appeal of drinking. This makes naltrexone compatible with harm-reduction and moderation-oriented goals as well as abstinence-based recovery.

The Sinclair Method

The Sinclair Method (TSM) is a specific approach in which oral naltrexone is taken about an hour before drinking, with the goal of "pharmacological extinction" — gradually unlearning the reinforcement of alcohol over weeks to months. The method has both proponents and skeptics in mainstream addiction medicine; it is used most often in patients who want to reduce rather than completely stop drinking.

Naltrexone for Opioid Use Disorder

Vivitrol is FDA-approved for OUD. It is most appropriate for patients who have completed opioid detoxification, who prefer an opioid-free approach, or who are unable to access buprenorphine. Mortality benefit appears similar to buprenorphine in selected patients, though the requirement for prior detoxification creates a higher barrier to entry.

Buprenorphine for Opioid Use Disorder

Buprenorphine products are FDA-approved for OUD treatment. Maintenance treatment can be open-ended; there is no required duration after which patients must taper. Long-term maintenance is associated with the strongest outcomes, and tapering off increases relapse and overdose risk.

Buprenorphine for Pain

Specific buprenorphine formulations are FDA-approved for chronic pain at lower doses than those used for OUD. The pharmacology — including ceiling effect on respiratory depression — makes buprenorphine an increasingly considered option in chronic pain when an opioid is needed.

Off-Label Naltrexone Uses

Low-dose naltrexone (LDN, typically 1.5–4.5 mg) has been studied in chronic pain, fibromyalgia, Crohn's disease, and multiple sclerosis. Evidence varies in quality. These are not standard of care.

Common and Serious Side Effects

Naltrexone

• Nausea (more common with Vivitrol; tends to improve)
• Headache
• Fatigue, dizziness
• Insomnia, anxiety
• Decreased appetite
• Injection site reactions (Vivitrol)
• Hepatic enzyme elevation (uncommon at usual doses)
• Risk of opioid overdose if a person uses opioids to overcome blockade or after naltrexone wears off

Buprenorphine

• Constipation
• Headache
• Sweating
• Insomnia
• Dry mouth
• Nausea
• QT prolongation (modest)
• Hepatic effects, particularly with concurrent hepatitis C
• Respiratory depression (less than full agonists; more risk when combined with benzodiazepines or alcohol)
• Tooth decay with sublingual products if oral hygiene is not maintained (FDA warning)

Precipitated Withdrawal

Both medications can precipitate severe withdrawal if started while opioids are active. Naltrexone requires 7–14 days of abstinence. Buprenorphine requires the patient to be in spontaneous withdrawal before induction. In the fentanyl era, the timing of buprenorphine induction has become more nuanced, with some clinicians using "low-dose induction" or "micro-induction" protocols.

Overdose Risk After Stopping

Patients who stop naltrexone or buprenorphine after a period of maintenance have lost their tolerance to opioids and are at greatly elevated risk of fatal overdose if they relapse. Discontinuation should be done thoughtfully, with naloxone (Narcan) available and with awareness of this risk.

Drug Interactions and Warnings

Other Opioids

Naltrexone blocks the effects of other opioids; patients on naltrexone who require pain management should plan with their clinician in advance for surgical or emergency contexts. Buprenorphine displaces other opioids and reduces their efficacy; pain management with full opioids while on buprenorphine requires specialist input.

Benzodiazepines and Alcohol

The combination of buprenorphine with benzodiazepines or alcohol increases the risk of respiratory depression and overdose. The FDA has explicitly stated, however, that this risk does not justify withholding buprenorphine from patients who also use these substances — the net mortality benefit of buprenorphine remains substantial. Risk management, education, and naloxone access are emphasized.

CYP3A4 Interactions

Buprenorphine is metabolized by CYP3A4. Strong inducers (rifampin, certain anticonvulsants) can reduce buprenorphine levels and trigger withdrawal. Strong inhibitors (some antifungals, certain HIV medications) can increase levels.

Hepatic Considerations

Both medications can affect liver function. Periodic monitoring is appropriate, particularly in patients with hepatitis C or significant liver disease.

Pregnancy

Buprenorphine and methadone are both standards of care for opioid use disorder in pregnancy. Buprenorphine monoproduct (Subutex) is often selected to avoid maternal/fetal exposure to naloxone, though combination products are also used. Neonatal abstinence syndrome (NAS) can occur and is managed with established neonatal care protocols.

Starting, Monitoring, and Stopping

Induction of Buprenorphine

Traditional induction requires the patient to be in mild-to-moderate spontaneous opioid withdrawal — typically 12–24 hours after short-acting opioids or longer for longer-acting opioids. The first dose is small (2–4 mg) and additional doses are given as withdrawal allows, building up to a stabilizing dose of typically 8–16 mg over the first day or two. In the fentanyl era, low-dose induction (microdosing) — starting with 0.5–1 mg doses while continuing some opioid use — has emerged as an alternative protocol for some patients, conducted under specialist supervision.

Induction of Naltrexone

Naltrexone requires complete opioid abstinence for 7–14 days. A naloxone challenge may be used to confirm absence of opioid dependence before the first naltrexone dose. Vivitrol induction is often the bottleneck, as patients may use during the abstinence window. Inpatient or residential induction is sometimes employed.

Maintenance

Buprenorphine maintenance is typically open-ended, with many patients on therapy for years. Doses are individualized but commonly 8–24 mg per day. Naltrexone maintenance is also open-ended; oral dosing is 50 mg per day, Vivitrol is monthly. Regular follow-up addresses substance use, mental health, social support, and side effects.

Urine Drug Screening

Periodic urine drug screening is common in MOUD programs, both to detect ongoing substance use (which informs treatment intensification rather than punishment in good clinical practice) and to confirm medication adherence. Approach matters: screening used to support, rather than to discipline, is more consistent with the evidence base.

Stopping

Decisions to discontinue MOUD should be deliberate and supported. Tapering buprenorphine slowly is generally preferred, with attention to relapse risk. Patients who relapse after stopping have lost tolerance and face elevated overdose risk. Naloxone should be readily accessible.

Special Populations

Pregnancy

Buprenorphine is the standard-of-care medication for opioid use disorder during pregnancy, alongside methadone. Treatment reduces maternal mortality, fetal exposure to substances and the chaos of active use, and risk of miscarriage and preterm birth. Naltrexone is not first-line in pregnancy because of less safety data and induction barriers. Decisions are coordinated with obstetric and addiction medicine teams.

Adolescents

Buprenorphine is FDA-approved for patients 16 and older. Treatment of adolescents with OUD should involve family, address school and developmental concerns, and combine medication with psychosocial support.

Older Adults

Older adults are increasingly affected by OUD, including from prescription opioids. Both buprenorphine and naltrexone can be used. Hepatic and cardiac monitoring may be more important in this group.

Co-occurring Conditions

Many patients with OUD or AUD have co-occurring depression, anxiety, PTSD, and other mental health conditions. Integrated treatment that addresses both substance use and mental health is associated with the best outcomes.

Criminal Justice Settings

Initiation or continuation of MOUD in correctional settings dramatically reduces post-release overdose mortality. Increasing access to buprenorphine and Vivitrol within jails and prisons has been a major policy and clinical focus.

Controversies and Modern Practice

The Stigma of Maintenance

A persistent and harmful misconception equates medication maintenance with continued addiction — the idea that "real recovery" requires abstinence from all medications. This view is contradicted by overwhelming evidence: maintenance treatment is associated with lower mortality, improved function, and better long-term outcomes than abstinence-based approaches alone. The mainstream addiction medicine community, the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, and major medical societies all recognize MOUD as evidence-based and life-saving.

X-Waiver Elimination

For two decades, US clinicians needed a special "X-waiver" to prescribe buprenorphine for OUD. The waiver requirement was eliminated in early 2023 as part of the Mainstreaming Addiction Treatment (MAT) Act. The change has expanded the prescriber pool, though many clinicians still face training gaps and institutional barriers.

The Fentanyl Era

The dominance of fentanyl in the illicit opioid supply has changed clinical practice. Fentanyl accumulates in fat tissue, making traditional buprenorphine induction more likely to precipitate withdrawal. Low-dose (micro-induction) protocols have been developed in response. Naloxone access and broader distribution have become more important than ever.

Naltrexone vs Buprenorphine

The X:BOT trial and other studies have compared buprenorphine and Vivitrol head-to-head. Outcomes are roughly comparable once both treatments are initiated, but Vivitrol has a higher early discontinuation rate because of the difficulty of completing the abstinence window before initiation. In most patients, buprenorphine has a lower barrier to entry. Patient preference, prior treatment, and clinical context all matter.

Alcohol Use Disorder Pharmacotherapy

Alcohol use disorder remains dramatically undertreated pharmacologically. Naltrexone, acamprosate, and disulfiram are the three FDA-approved AUD medications, yet only a small minority of people with AUD ever receive any of them. Expanding access is a major focus in modern addiction medicine.

What Patients Should Know

Treatment Is Not "Trading One Addiction for Another"

Buprenorphine maintenance is medical treatment for a medical condition — comparable to insulin for diabetes or antiretrovirals for HIV. Although the medication produces physical dependence, the constellation of compulsive use, harm to self and others, and loss of control that defines addiction is replaced by stability. Many people in long-term maintenance work, parent, study, and live fully without active addiction.

Carry Naloxone

Anyone with a history of opioid use disorder — whether on maintenance, in early recovery, or actively using — should have naloxone available. Family, friends, and roommates should know how to use it. Naloxone is now available over the counter in the United States.

Coordinate Pain Management

Patients on buprenorphine or naltrexone who face surgery, injury, or labor pain should have a plan in place with their prescriber. Adequate pain control is possible but requires coordination — sometimes increasing the buprenorphine dose, sometimes using regional anesthesia or non-opioid options, and rarely temporarily transitioning off the medication.

Tell All Your Clinicians

Buprenorphine and naltrexone status should be clearly communicated to every clinician — primary care, emergency medicine, dentistry, surgery, obstetrics. This prevents harmful prescribing decisions and ensures appropriate care.

Dental Health

The FDA has noted dental problems associated with sublingual buprenorphine. Good oral hygiene — rinsing the mouth with water after the dose dissolves, regular dental care, and avoiding sugary substances around the dose — helps protect teeth.

Recovery Is Multidimensional

Medication is foundational but is most effective when combined with psychosocial support, mental health care, attention to social determinants (housing, employment, relationships), and connection with community. There is no single right path to recovery, and the best approach is one that fits the individual.